Literature DB >> 30584584

Stability of Frequency of Severe Chronic Obstructive Pulmonary Disease Exacerbations and Health Care Utilization in Clinical Populations.

Denitza P Blagev1,2, Dave S Collingridge1,3, Susan Rea3,4, Valerie G Press5, Matthew M Churpek5, Kyle Carey5, Richard A Mularski6,7, Siyang Zeng8,9, Mehrdad Arjomandi8,9.   

Abstract

Rationale: Although chronic obstructive pulmonary disease (COPD) exacerbation frequency is stable in research cohorts, whether severe COPD exacerbation frequency can be used to identify patients at high risk for future severe COPD exacerbations and/or mortality is unknown.
Methods: Severe COPD exacerbation frequency stability was determined in 3 distinct clinical cohorts. A total of 17,450 patients with COPD in Intermountain Healthcare were categorized based on the number of severe COPD exacerbations per year. We determined whether exacerbation frequency was stable and whether it predicted mortality. These findings were validated in 83,134 patients from the U.S. Veterans Affairs (VA) nationwide health care system and 3326 patients from the University of Chicago Medicine health system.
Results: In the Intermountain Healthcare cohort, the majority (84%, 14,706 patients) had no exacerbations in 2009 and were likely to remain non-exacerbators with a significantly lower 6-year mortality compared with frequent exacerbators (2 or more exacerbations per year) (25% versus 57%, p<0.001). Similar findings were noted in the VA health system and the University of Chicago Medicine health system. Non-exacerbators were likely to remain non-exacerbators with the lowest overall mortality. In all cohorts, frequent exacerbator was not a stable phenotype until patients had at least 2 consecutive years of frequent exacerbations. COPD exacerbation frequency predicted any cause mortality. Conclusions: In clinical datasets across different organizations, severe COPD exacerbation frequency was stable after at least 2 consecutive years of frequent exacerbations. Thus, severe COPD exacerbation frequency identifies patients across a health care system at high risk for future COPD-related health care utilization and overall mortality.

Entities:  

Keywords:  COPD exacerbation; chronic obstructive pulmonary disease; health care utilization; stability

Year:  2018        PMID: 30584584      PMCID: PMC6296787          DOI: 10.15326/jcopdf.5.3.2017.0183

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN: 2372-952X


  5 in total

1.  Developing a Machine Learning Model to Predict Severe Chronic Obstructive Pulmonary Disease Exacerbations: Retrospective Cohort Study.

Authors:  Siyang Zeng; Mehrdad Arjomandi; Yao Tong; Zachary C Liao; Gang Luo
Journal:  J Med Internet Res       Date:  2022-01-06       Impact factor: 5.428

2.  The Association between Medical Utilization and Chronic Obstructive Pulmonary Disease Severity: A Comparison of the 2007 and 2011 Guideline Staging Systems.

Authors:  Chen-Yu Wang; Chen Liu; Hsien-Hui Yang; Pei-Ying Tseng; Jong-Yi Wang
Journal:  Healthcare (Basel)       Date:  2022-04-13

3.  Increased mortality associated with frequent exacerbations in COPD patients with mild-to-moderate lung function impairment, and smokers with normal spirometry.

Authors:  Spyridon Fortis; Emily S Wan; Ken Kunisaki; Patrick Tel Eyck; Zuhair K Ballas; Russell P Bowler; James D Crapo; John E Hokanson; Chris Wendt; Edwin K Silverman; Alejandro P Comellas
Journal:  Respir Med X       Date:  2020-12-29

4.  Laboratory-based Intermountain Validated Exacerbation (LIVE) Score stability in patients with chronic obstructive pulmonary disease.

Authors:  Denitza P Blagev; Dave S Collingridge; Susan Rea; Kyle A Carey; Richard A Mularski; Siyang Zeng; Mehrdad Arjomandi; Valerie G Press
Journal:  BMJ Open Respir Res       Date:  2020-02

5.  Should the number of acute exacerbations in the previous year be used to guide treatments in COPD?

Authors:  Mohsen Sadatsafavi; James McCormack; John Petkau; Larry D Lynd; Tae Yoon Lee; Don D Sin
Journal:  Eur Respir J       Date:  2021-02-11       Impact factor: 16.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.